4
Platforms
94-95%
AMD Flagship Accuracy
Q1 2027
Target Launch

Multi-Platform Risk Assessment Portfolio

Transforming preventive healthcare across multiple therapeutic areas

Risk Assessment Platforms
Research &
PoC
CLIA Validation
& Launch
Early Revenue
Generation
FDA Enhancement
(Parallel)
Revenue Scale &
Market Leadership

AMD Risk Assessment & Prediction

Blood-based early detection platform

Endometriosis Risk Analysis

Women's health diagnostic platform

Alzheimer's Risk Prediction

Neurological assessment tools

Autism Risk Assessment Tools

Developmental screening platform

AMD Commercialization Strategy: Our lead platform follows the proven CLIA LDT pathway modeled after Exact Sciences' Oncotype DX ($600M+ annual revenue without FDA approval). Q1 2027 launch generates early revenue while FDA clearance is pursued in parallel for enhanced market access and physician confidence, not as a prerequisite for commercialization.

Platform Strategy & Scalability

Lead Product: AMD Risk Assessment drives initial market entry and validation
Technology Foundation: Blood-based biomarker analysis platform expandable across conditions
Sequential Expansion: Systematic rollout to additional therapeutic areas after AMD success
Market Validation: Each platform leverages proven regulatory and reimbursement pathways
Revenue Diversification: Multiple revenue streams reduce market risk and maximize growth potential

Strategic Advantage: Our development pipeline positions A1 Diagnosis as a comprehensive platform company rather than a single-product venture. This multi-platform approach provides significant competitive advantages, diversified revenue streams, and enhanced investor value proposition.

Explore Our Research

Learn more about the science behind our risk assessment platforms and how to get involved.

View Publications Investor Contact